ArticleFrontiers in immunology2025
CD71+ erythroid cells as a potential early biomarker for hemodynamic significant patent ductus arteriosus in preterm infants.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants is associated with increased mortality and morbidity. Early and accurate identification of infants at risk for PDA is critical for improving outcome. Perinatal inflammation is a known risk factor of PDA. CD71+ erythroid cells (CECs) are immature red blood cells with immunomodulatory roles and show variable abundance in preterm infants. We aimed to examine the proportion of CECs in preterm infants and investigate association with PDA. Methods: In this prospective study, we evaluated the association between CEC levels and the development of hsPDA in a cohort of 108 preterm infants born before 37 weeks of gestation. CEC levels were quantified by flow cytometry within 12 hours of birth. The presence of hsPDA was assessed by echocardiography between days 3 and 7 after birth. Results: CEC levels showed a significant inverse relationship with gestational age (CEC(%) = -0.4419 × Gestational Age + 18.7029, p<0.001). CEC levels were also inversely correlated with hemoglobin, red blood cells, white blood cells, and platelets (all Discussion: These results suggest that early measurement of CEC levels can identify preterm infants at high risk for hsPDA prior to echocardiographic diagnosis. As a potential predictive biomarker, CECs may improve risk stratification and guide timely intervention, ultimately enhancing clinical outcomes. Further research is needed to elucidate the mechanisms linking CECs to hsPDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.